ClinicalTrials.Veeva

Menu

Spontaneous Preterm Birth Marker Test

S

Sprim Advanced Life Sciences

Status

Unknown

Conditions

Preterm Delivery

Study type

Observational

Funder types

Other

Identifiers

NCT03123926
BAB-0316

Details and patient eligibility

About

The prediction of preterm birth is beneficial because it initiates early treatment to minimize risk. It defines a population at risk to provide particular treatment and may lead us to a better understanding the mechanisms of preterm birth. The understanding of the mechanisms and etiology consequently leads to the possibility of early intervention and effective management aiming at preventing preterm birth. Five most common interventions for preventing and treating preterm birth are antibiotics, cervical cerclage, bed rest, progesterone, and tocolytic therapy. However, there are insufficient evidence showing the efficacy of cerclage and bed rest; antibiotics may only delay but not prevent the preterm birth; the use of certain tocolytics needs to be considered against the possible adverse effects. The early detection of pregnant women with high risk for preterm delivery would be the ideal solution to prevent preterm birth. However, to date, there is inadequate literature and little knowledge of diagnosis, treatment, prevention and prediction of preterm birth.

Enrollment

600 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pregnancy women aged ≥ 18 years with pregnancy at 24 to 28 weeks of gestation.

Exclusion criteria

  • Subjects with any conditions or diseases that investigator considers it is not appropriate to enter the study.

Trial contacts and locations

1

Loading...

Central trial contact

Orawan Suitthimeathegorn; Jillian De Leon

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems